Combination of Osimertinib and Vascular Endothelial Growth Factor Receptor Inhibitors for EGFR-Mutated Non–Small Cell Lung Cancer: Old or New Regimen? Clinical trials frequently include multiple end ...

The conduct of cancer clinical research in the United States is supported by both private and public sponsors. Industry aims to obtain new drug approvals. Federally sponsored trials examine a broad ...

Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose ...

View all available purchase options and get full access to this article. The following represents disclosure information provided by authors of this manuscript. All relationships are considered ...

Correlative Science in the Cooperative Group System—Re-Engineering for Success Achieving opioid pharmacoequity or ensuring access to evidence-based pharmacologic therapies regardless of race and ...

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Randomized Controlled Trial ...

JCO Journals have adopted a format-free submission policy (EZSubmit). New submissions are not scrutinized for compliance with our formatting guidelines (reference style, order of components, figure ...

In 2012, the National Academies of Sciences, Engineering, and Medicine convened a committee charged with addressing the quality of cancer care in the United States and providing recommendations to ...

Smartwatch Biometrics in the Electronic Medical Record: Time for a New Vital Sign? The following represents disclosure information provided by authors of this manuscript. All relationships are ...

JCO is the primary forum of scientific discourse for the American Society of Clinical Oncology (ASCO). Published three times a month, JCO is the foremost peer-reviewed journal focusing on clinical ...

Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial Authors retain all ...